Acorda to stop Plumiaz development to treat epilepsy seizure clusters
Plumiaz failed to demonstrate its bioequivalence to Diastat rectal gel, which was required to support a refiling of the nasal spray’s new drug application earlier planned for the
QIAGEN’s Digital Insights bioinformatics division is set to integrate NVIDIA’s accelerated computing and the BioNeMo platform to enhance AI-driven drug discovery.
The engagement will leverage the capabilities of Inovalon’s data platforms and Avalere’s extensive industry experience, to support Bristol-Myers Squibb’s real-world outcomes and value-based contracting initiatives. The application of
EVK-001 is the Company’s novel nasal spray for delivery of metoclopramide for the symptomatic relief of acute and recurrent diabetic gastroparesis in women. Pursuant to the agreement, COSMA
Data from a prior Phase 1 study of MM-151 supports further clinical evaluation of the investigational therapy in patients with metastatic colorectal cancer. The initiation of this study